ArticleInternational journal of general medicine2025
Factors Associated With Multi-Drug Resistant Organisms Among Bronchiectasis Patients: A Retrospective Study of Bronchiectasis Patients in Jordan.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology, risk factors and clinical outcomes of multidrug-resistantJournal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchiectasis, a respiratory ailment, significantly impacts the life expectancy of individuals. This study aimed to explore the prevalence of multidrug-resistant organisms (MDROs) among bronchiectasis patients, the resistance patterns within various antibiotic classes, and the associated factors with these organisms. Methods: A retrospective observational analysis was conducted on adult bronchiectasis patients attending clinics at Jordan University Hospital. The diagnosis of bronchiectasis was established through lung Computerized Tomography (CT) scans and clinical symptom assessment. Results: The study encompassed 235 patients, revealing a notably higher occurrence of MDROs among non-cystic fibrosis patients compared to their counterparts (P-value=0.001). Additionally, MDROs showed significant associations with the usage of inhaled beta agonists, anti-cholinergics, corticosteroids, and inhaled antibiotics (P-value<0.050). Patients with MDROs experienced a significantly elevated mean number of hospitalizations, exacerbations, and antibiotic courses compared to their counterparts (P-value<0.050). Moreover, those with MDROs exhibited a higher incidence of requiring O2 device support and faced an increased risk of mortality (P-value<0.050). Conclusion: The observational nature of our study limits the associations in our study. However, we provided evidence that it is imperative for clinicians to assess their bronchiectasis patients for MDRO risk factors, facilitating appropriate initial antibiotic selection. Nevertheless, the validation of MDRO risk factors necessitates further exploration through larger studies with extended follow-up periods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.